Amylyx Pharmaceuticals (AMLX) Accumulated Depreciation (2021 - 2025)

Amylyx Pharmaceuticals' Accumulated Depreciation history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 14.35% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $1.6 million, a 14.35% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 14.35% from the prior year.
• Accumulated Depreciation rose to $1.6 million in Q4 2025 per AMLX's latest filing, from $1.4 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $1.6 million in Q4 2023 and bottomed at $53000.0 in Q4 2021.
• The 5-year median for Accumulated Depreciation is $1.4 million (2024), against an average of $1.0 million.
• Across the five-year window, Accumulated Depreciation soared 918.87% in 2022 and decreased 16.52% in 2024, its largest moves.
• Year by year, Accumulated Depreciation stood at $53000.0 in 2021, then surged by 918.87% to $540000.0 in 2022, then surged by 201.48% to $1.6 million in 2023, then decreased by 16.52% to $1.4 million in 2024, then rose by 14.35% to $1.6 million in 2025.
• Per Business Quant, the three latest AMLX Accumulated Depreciation figures stand at $1.6 million (Q4 2025), $1.4 million (Q4 2024), and $1.6 million (Q4 2023).